Indication intelligence, analysis and sector perception

Kite Pharma (KITE) strategic partnership with Vitruvian Networks - BUY

December 14, 2016 10:00am

Creates a software solution for supporting commercial availability of T-cell therapies while KITE jumps +2.47%

The tie-up will leverage KITE's expertise in clinical development, manufacturing, supply chain management and commercialization in engineered T-cell therapies with Vitruvian's hybrid expertise in cloud-based software and data analytics solutions in cell and gene therapy manufacturing and delivery

The Bottom Line: Under the latest partnership, the companies will design and develop a platform for patients, physicians and treatment centers to support the commercial use of FDA-approved T-cell therapies. Also, the software will be designed to support commercial-scale ordering, logistics, monitoring and delivery of autologous cell therapies, including Kite's lead candidate axicabtagene ciloleucel (KTE-C19).

*** As per the terms of the agreement, the companies will contribute resources and relevant experience for the partnership. Financial terms of the agreement were not disclosed.

KITE is UP +$1.15 or +2.47% to $47.89 post the open …

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

14 min ago
RegMed Investors’ (RMi) pre-open: “uncle algo” withdraws upside from share pricing, my thoughts, some recover

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.